home / stock / cmnd:cc / cmnd:cc news

CMND:CC News and Press, Clearmind Medicine Inc. From 09/18/23

Stock Information
Company Name: Clearmind Medicine Inc.
Stock Symbol: CMND:CC
Market: CNQC
Website: clearmindmedicine.com
Menu
CMND:CC CMND:CC Quote CMND:CC Short CMND:CC News CMND:CC Articles CMND:CC Message Board
Get CMND:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
CMND:CC - Clearmind Medicine Closes US$2.25 Million Public Offering

Tel Aviv, Israel / Vancouver, Canada, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated he...
CMND:CC - Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering

Tel Aviv, Israel / Vancouver, Canada, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated he...

CMND:CC - Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder

Tel Aviv, Israel / Vancouver, Canada, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-trea...

CMND:CC - Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company

Tel Aviv, Israel / Vancouver, Canada, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treat...
CMND:CC - SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia and dystonia known to occur in several rapid, non-rhythmic, abnormal movements disorders including Touret...

CMND:CC - Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve maj...

CMND:CC - Clearmind Medicine Announces Share-Based Payment for the Company's Consultants

Tel Aviv, Israel / Vancouver, Canada, July 17, 2023 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under...
CMND:CC - Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board

Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treat...

CMND:CC - SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome

The treatment combines SciSparc's Palmitoylethanolamide (PEA) , the active pharmaceutical ingredient of its proprietary CannAmide ™ , and Clearmind’s MEAI, a novel proprietary psychedelic treatment for various addictions ...

CMND:CC - Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

The treatment combines Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™ Tel Aviv, Israel / Vancouver, Canada, June 16, 2023 (GLOBE NEWSWIRE) -- C...
Previous 10 Next 10